Coronary Stents: Impact on Cardiac Mortality vs. Symptom Relief

Impact on Mortality

In acute myocardial infarction, primary PCI with stenting has shown mortality benefits compared to fibrinolytic therapy (5.9% vs 7.7%, OR 0.75, 95% CI 0.60 to 0.94) 1
Stent implantation in unstable coronary artery disease helps to mechanically stabilize disrupted plaque, which is particularly beneficial in high-risk lesions 2, 3
The mortality rate associated with percutaneous coronary intervention in acute settings is generally very low 3, 4

PCI with stenting consistently demonstrates superior control of angina symptoms compared to medical therapy alone 5, 6
The European Society of Cardiology recommends PCI with stenting for symptom relief in patients with stable coronary artery disease who have not responded to medical therapy 5, 6

Drug-eluting stents (DES) show consistently better treatment effects compared to bare-metal stents (BMS), reducing restenosis and major adverse cardiac events including target vessel revascularization 5, 7
Coronary stenting reduces the rate of restenosis and the need for repeat PCI compared to balloon angioplasty alone 5, 6

For multivessel disease, CABG has shown a mortality benefit compared to PCI at 5-8 years, as well as significantly less angina and less need for repeat revascularization 7
The American Heart Association recommends CABG for patients with left main coronary artery disease or multivessel disease with high-grade stenosis of the proximal LAD 8

For acute coronary syndromes, particularly STEMI, stenting offers mortality benefits and should be preferred when timely access is available 1
For stable coronary artery disease, stenting should be considered primarily for symptom relief when medical therapy is inadequate 5, 6
In high-risk anatomical scenarios (left main disease, multivessel disease, especially in diabetics), CABG may offer mortality benefits over stenting 8, 7
The choice between PCI and CABG should consider factors such as anatomical complexity, comorbidities, and patient preferences 7, 9

Failing to consider the higher risk of repeat revascularization with PCI compared to CABG, particularly in complex disease 7
Not maintaining adequate antiplatelet therapy after stenting, which is crucial for preventing stent thrombosis 10

Stent placement treats only the "culprit lesion" but doesn't prevent new plaque ruptures at other sites in the coronary tree, which are often the cause of fatal cardiac events 11
Stent thrombosis, while rare, carries a high mortality risk and can occur despite stent placement 11
Early stent thrombosis (within first 30 days) is associated with a 30-fold greater risk of mortality 12
Premature discontinuation of dual antiplatelet therapy significantly increases the risk of stent thrombosis and subsequent mortality 12
Bare-metal stent thrombosis is most common in the first 2-4 weeks after placement but becomes exceedingly rare (<0.1%) after endothelialization occurs 11, 13

Dual antiplatelet therapy adherence is crucial after stenting to prevent thrombosis, but even with optimal therapy, stents don't significantly reduce long-term cardiac mortality in stable disease 12

The American College of Cardiology recommends dual antiplatelet therapy (DAPT) for a critical window, especially within the first 30 days after stent placement, to prevent stent thrombosis 14
The American Heart Association suggests that first-generation drug-eluting stents (DES) require 12 months of DAPT, while newer-generation stents may allow shorter durations, such as 6 months for stable disease or 3 months for high bleeding risk 15, 16

The American College of Cardiology advises against discontinuing DAPT prematurely, as this increases the risk of catastrophic stent thrombosis 14
The American Heart Association recommends maintaining aggressive secondary prevention, including statins, antiplatelet therapy, and risk factor modification, indefinitely to manage the underlying atherosclerotic disease 17